RAPT Therapeutics to be Acquired by GlaxoSmithKline for $58.00 Per Share in Tender Offer

summarizeSummary

RAPT Therapeutics has entered into a definitive agreement to be acquired by GlaxoSmithKline for $58.00 per share in an all-cash tender offer, followed by a merger.

check_boxKey Events

• Definitive Merger Agreement

  RAPT Therapeutics has entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC (Parent) and GSK plc (Ultimate Parent).

• Acquisition Price

  GSK will acquire all outstanding shares of RAPT Therapeutics common stock for $58.00 per share in cash.

• Transaction Structure

  The acquisition will be effected through a tender offer, followed by a second-step merger under Section 251(h) of Delaware law.

• Offer Commencement

  The tender offer is expected to commence no later than February 2, 2026.

auto_awesomeAnalysis

This filing announces a definitive agreement for GlaxoSmithKline (GSK) to acquire RAPT Therapeutics. The offer price of $58.00 per share represents a significant premium to the company's 52-week high and provides immediate liquidity and a clear exit for shareholders. This is a thesis-altering event, as RAPT Therapeutics will cease to be an independent public entity, integrating its pipeline and operations into GSK. Investors should tender their shares once the offer commences.